CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $400,334 | +23.2% | 7,131 | -0.7% | 0.01% | +8.3% |
| Q1 2023 | $324,887 | +11.2% | 7,183 | -0.1% | 0.01% | 0.0% |
| Q4 2022 | $292,233 | -44.1% | 7,189 | -10.1% | 0.01% | -47.8% |
| Q3 2022 | $523,000 | -17.6% | 7,998 | -8.5% | 0.02% | -14.8% |
| Q2 2022 | $635,000 | +31.7% | 8,738 | +12.7% | 0.03% | +42.1% |
| Q1 2022 | $482,000 | -11.2% | 7,756 | -0.2% | 0.02% | -5.0% |
| Q4 2021 | $543,000 | +31.2% | 7,773 | +92.4% | 0.02% | +11.1% |
| Q3 2021 | $414,000 | +27.4% | 4,041 | +79.4% | 0.02% | +12.5% |
| Q2 2021 | $325,000 | – | 2,253 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |